Trial Profile
A Phase 2 Open-Label Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV VLP], Aluminum Hydroxide Adjuvanted)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jul 2023
Price :
$35
*
At a glance
- Drugs VRC-CHKVLP059-00-VP (Primary) ; Alum; Aluminium hydroxide
- Indications Chikungunya virus infections
- Focus Pharmacodynamics
- Sponsors Bavarian Nordic
- 18 Jul 2022 Status changed from active, no longer recruiting to completed.
- 11 Jan 2022 Planned End Date changed from 1 Jan 2022 to 1 Jun 2022.
- 11 Jan 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Jun 2022.